SCHEMBL167840

SCHEMBL167840

COC(=O)c1cc(Br)c(C(Br)Br)cc1OC(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
KDM4E B2RXH2 4/20 0.37
CFD P00746 2/20 0.36
SOS1 Q07889 1/20 0.36
HSD17B10 Q99714 2/20 0.35
TNFSF11 O14788 1/20 0.35
NR4A2 P43354 1/20 0.35
HTT P42858 2/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168791 0.84 GAA (0.46) POLBKDM4ECFDHSD17B10TNFSF11
SCHEMBL166010 0.81 KDM4E (0.41) POLBKDM4ECFDSOS1HSD17B10
SCHEMBL167967 0.80 POLB (0.51) POLBKDM4ECFDSOS1HSD17B10
SCHEMBL23094640 0.80 CFD (0.39) KDM4ECFDHSD17B10TNFSF11HTT
SCHEMBL16637297 0.77 SOS1 (0.44) POLBKDM4ESOS1HSD17B10NR4A2
SCHEMBL166372 0.77 POLB (0.48) POLBKDM4ECFDSOS1HSD17B10
SCHEMBL166131 0.77 KDM4E (0.39) POLBKDM4ECFDSOS1HSD17B10
SCHEMBL7417048 0.77 SMN1; SMN2 (0.44) POLBKDM4ECFDHSD17B10HTT
SCHEMBL19838683 0.77 PRKDC (0.50) POLBKDM4ECFDSOS1HSD17B10
SCHEMBL17185142 0.75 CYP4F2 (0.39) POLBKDM4ECFDSOS1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3494118-B1 NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-06-21 EP disclosed
US-10562910-B2 Nitrogen-containing tricyclic compounds and uses thereof in medicine NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) 2020-02-18 US disclosed
US-20190169203-A1 NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-06-06 US disclosed
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562910-B2 Nitrogen-containing tricyclic compounds and uses thereof in medicine NR1H4, SLC10A1, SLC10A2 POLB 2798/4885KDM4E 4829/4885CFD 1905/4885
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 POLB 1496/4885KDM4E 1447/4885CFD 4883/4885
US-20190169203-A1 NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE NR1H4, SLC10A1, SLC10A2 POLB 2798/4885KDM4E 4829/4885CFD 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.